This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
myasthenia-gravis
Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune NMJ disease; AChR antibodies (85%) activate complement → AChR destruction → fatigable weakness; MuSK antibodies (6%) cause IgG4-mediated dysfunction. Pyridostigmine, steroids, thymectomy, eculizumab, and efgartigimod are treatments.
Entry Metadata
| Field | Value |
|---|---|
| ID | myasthenia-gravis |
| Name | Myasthenia Gravis |
| Status | draft |
| Last reviewed | 2026-06-07 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570-2581. · PubMed 28029925
- Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT). Lancet Neurol. 2021;20(7):526-536. · PubMed 34146511
- Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN). Lancet Neurol. 2017;16(12):976-986. · PubMed 29066163